Avacta Group PLC Director Dealing and Issue of Equity (1232K)
July 05 2017 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 1232K
Avacta Group PLC
05 July 2017
05 July 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director Dealing and Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that application
has been made for 4,345 new ordinary shares of 10p each (the "New
Ordinary Shares") to be admitted to trading on AIM on 12 July 2017
("Admission").
The New Ordinary Shares have been allotted pursuant to the
purchase by Michael Albin, Non-Executive Director of the Company,
of New Ordinary Shares in accordance with the terms set out in the
Company's announcement of 23 February 2016.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 68,397,433. Shareholders may use
this figure as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0)
WG Partners 203 705 9318
David Wilson Tel: +44 (0)
Nigel Barnes 203 705 9217
Claes Spang www.wgpartners.co.uk
Media Enquiries Tel: +44 (0)
FTI Consulting 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
------- -----------------------------------------------------------------------------------------------------------------------------
a) Name Michael Albin
------- ---------------------------- -----------------------------------------------------------------------------------------------
2. Reason for the Notification
------- -----------------------------------------------------------------------------------------------------------------------------
a) Position/status Non - Executive Director
------- ---------------------------- -----------------------------------------------------------------------------------------------
b) Initial Initial notification
notification/Amendment
------- ---------------------------- -----------------------------------------------------------------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
------- -----------------------------------------------------------------------------------------------------------------------------
a) Name Avacta Group Plc
------- ---------------------------- -----------------------------------------------------------------------------------------------
b) LEI 2138009U3EG31OPMGH36
------- ---------------------------- -----------------------------------------------------------------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
------- -----------------------------------------------------------------------------------------------------------------------------
a) Description of Ordinary shares
the Financial of 10p
instrument, type
of instrument
-------
Identification GB00BYYW9G87
code
------- ---------------------------- -----------------------------------------------------------------------------------------------
b) Nature of the As set out in the Company's announcement of 23 February 2016, on 22 February 2016
transaction Mr Albin
entered into a binding commitment to purchase new Avacta shares amounting to 50% of
his contractual
non-executive director fee per quarter and the New Ordinary Shares represent his
investment
for the period of 1 April 2017 to 30 June 2017.
------- ---------------------------- -----------------------------------------------------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- --------------
86.3 pence 4,345
---------------- --------------
------- ---------------------------- -----------------------------------------------------------------------------------------------
d) Aggregated information:
* Aggregated volume See above
* Price
------- ---------------------------- -----------------------------------------------------------------------------------------------
e) Date of the transaction 4 July 2017
------- ---------------------------- -----------------------------------------------------------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction Market (XLON)
------- ---------------------------- -----------------------------------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKQDBABKDOOK
(END) Dow Jones Newswires
July 05, 2017 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
